3.15
0.05 (1.61%)
| Previous Close | 3.10 |
| Open | 3.16 |
| Volume | 229,641 |
| Avg. Volume (3M) | 171,798 |
| Market Cap | 12,616,475 |
| Price / Sales | 1.86 |
| Price / Book | 1.43 |
| 52 Weeks Range | |
| Earnings Date | 9 Aug 2023 - 14 Aug 2023 |
| Operating Margin (TTM) | -2,073.29% |
| Diluted EPS (TTM) | -1.43 |
| Quarterly Revenue Growth (YOY) | 2,170.70% |
| Total Debt/Equity (MRQ) | 121.86% |
| Current Ratio (MRQ) | 0.760 |
| Operating Cash Flow (TTM) | -9.30 M |
| Levered Free Cash Flow (TTM) | -4.11 M |
| Return on Assets (TTM) | -73.20% |
| Return on Equity (TTM) | -490.37% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Instruments & Supplies (US) | Mixed | Mixed |
| Medical Instruments & Supplies (Global) | Bullish | Mixed | |
| Stock | Predictive Oncology Inc. | Mixed | Mixed |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 0.0 |
| Average | 0.14 |
|
Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Pittsburgh segment that provides services which include the application of AI using its proprietary biobank of 150,000+ tumor samples. It also creates proprietary 3D culture models used in drug development; Birmingham segment that provides contract services and research focused on solubility improvements, stability studies, and protein production; and Eagan segment that produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. It derives maximum revenue from Eagan Segment. |
|
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Investment Style | Small Value |
| % Held by Insiders | 1.27% |
| % Held by Institutions | 2.07% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |